KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) Net Margin (2020 - 2026)

AbCellera Biologics filings provide 7 years of Net Margin readings, the most recent being 519.12% for Q1 2026.

  • Quarterly Net Margin rose 55812.0% to 519.12% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 181.75% through Mar 2026, up 54448.0% year-over-year, with the annual reading at 194.88% for FY2025, 36995.0% up from the prior year.
  • Net Margin hit 519.12% in Q1 2026 for AbCellera Biologics, down from 19.94% in the prior quarter.
  • Across five years, Net Margin topped out at 53.25% in Q1 2022 and bottomed at 1077.24% in Q1 2025.
  • Average Net Margin over 5 years is 381.55%, with a median of 407.98% recorded in 2024.
  • Peak annual rise in Net Margin hit 65748bps in 2025, while the deepest fall reached -66926bps in 2025.
  • AbCellera Biologics' Net Margin stood at 138.75% in 2022, then crashed by -270bps to 513.67% in 2023, then crashed by -32bps to 677.43% in 2024, then soared by 97bps to 19.94% in 2025, then crashed by -2503bps to 519.12% in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Net Margin are 519.12% (Q1 2026), 19.94% (Q4 2025), and 637.84% (Q3 2025).